Compare FJET & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FJET | VYGR |
|---|---|---|
| Founded | 2022 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 275.1M | 227.2M |
| IPO Year | N/A | 2015 |
| Metric | FJET | VYGR |
|---|---|---|
| Price | $4.95 | $3.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | ★ 1.1M | 488.9K |
| Earning Date | 04-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,135,000.00 |
| Revenue This Year | N/A | $34.04 |
| Revenue Next Year | N/A | $7.92 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.39 | $2.65 |
| 52 Week High | $28.56 | $5.55 |
| Indicator | FJET | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 39.66 | 47.72 |
| Support Level | $4.45 | $3.72 |
| Resistance Level | $8.47 | $4.31 |
| Average True Range (ATR) | 0.71 | 0.16 |
| MACD | -0.06 | -0.02 |
| Stochastic Oscillator | 8.98 | 31.91 |
Starfighters Space Inc is a commercial aerospace company based at NASA's Kennedy Space Center in Florida. The company operates supersonic aircraft capable of sustained Mach 2 flight and configured to carry payloads to high altitudes for air launch to space. Its activities include air launch operations, pilot and space flight training, support research, hypersonic testing, and other aerospace development programs. The company provides commercial space services and related aerospace capabilities.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.